Field report N-77 / M8 · sheet /expansion

Expansion & MarketsFiled from the territory

Ellipses Pharma targets £450m-£500m London listing in February

Ellipses Pharma, backed by Mubadala at 45 per cent and celebrities including Jimmy Carr, is preparing a London reverse takeover valuing it at up to £500m.

Grid
N-77 / M8
Surveyed
November 16, 2026
Reading
3 min read
Correspondent
Priya Raman
Celebrity-backed cancer treatment venture eyes London listing
Fig. N-77 / M8Celebrity-backed cancer treatment venture eyes London listing — PIX1861 / pixabay

Field notes

  1. Ellipses Pharma targets a London listing valuation of £450m-£500m as soon as February.
  2. Mubadala Investment Company of Abu Dhabi holds a 45 per cent stake, the largest single holding.
  3. The listing proceeds via reverse takeover of Wolfram Resources, a precious metals cash shell.
  4. The company has invested roughly £185m in its drug pipeline and employs around 40 people.
  5. Berenberg is reported to be managing the deal; RBC and Pharma Ventures are lined up for out-licensing advice.

Ellipses Pharma is preparing to list on the London Stock Exchange at a valuation of between £450m and £500m, as soon as February, according to reports in The Times. That's a decision worth pausing on. The clinical-stage oncology venture had spent months flirting with rival venues, and London wasn't the favourite.

The vehicle for the move is a reverse takeover (a deal where a private company buys an already-listed shell and inherits its market position) of Wolfram Resources, a cash shell previously focused on precious metals exploration across central Asia. Reverse takeovers cut the time and cost of going public compared with a traditional initial public offering. The Nasdaq has seen a flurry of them this year; now London gets one of its own.

Who is behind Ellipses?

The company was founded by Sir Chris Evans, the British biotech entrepreneur who has founded and listed numerous companies including Enzymatix and Celsis. Its investor register mixes three very different worlds:

  • Sovereign wealth: Abu Dhabi's Mubadala Investment Company holds a 45 per cent stake, making it the single largest shareholder. Waleed al-Mokarrab al-Muhairi, Mubadala's deputy chief executive, sat on the Ellipses board until March 2025.
  • British business figures: Steve Morgan, founder of housebuilder Redrow, and Sir Tom Hunter's investment vehicle West Coast Capital.
  • Celebrity money: comedian Jimmy Carr and composer Andrew Lloyd Webber have both invested.

The company is not a lab-scale startup. It employs around 40 people, drawn mainly from big pharmaceutical companies, and has invested roughly £185m in its drug pipeline to date. It also launched a clinical trial programme in the UAE in December 2024.

Why did London beat New York and Hong Kong?

Evans had been weighing a listing away from London for some time. The Nasdaq was under serious consideration as Ellipses' home, and Hong Kong was floated as a possible venue in 2025, according to the reports.

The pivot back to London changes the arithmetic. On the deal side, private bank Berenberg is reported to have been appointed to help manage the transaction. Ellipses is also preparing to appoint non-executive directors to its board before the listing completes.

There's a commercial logic too. Royal Bank of Canada and Pharma Ventures, an M&A advisory firm, are understood to have been lined up to advise on potential out-licensing deals (selling the rights to a drug to a larger pharma company in exchange for upfront payments and royalties) with big pharma. A formal announcement could come as soon as this week.

What does it mean for London's market?

A listing at this valuation would hand London a much-needed boost. The exchange has been absorbing a wave of delistings alongside a continued exodus of IPOs, with listings recently falling to their lowest levels since 2023.

The biotech and pharmaceutical sector is where the win stings most for rivals. London has watched company after company eye opportunities in America. FTSE heavyweight AstraZeneca has spent the last year pivoting closer to the US, upgrading its listing on the New York Stock Exchange.

Ellipses choosing London over both New York and Hong Kong is a modest counter-signal. One deal doesn't reverse a trend, and a £450m-£500m valuation is small change next to the FTSE 100's pharma giants. But it puts a clinical-stage oncology company with celebrity backers, sovereign wealth money and a £185m pipeline on the London register at a moment when the market badly needed a win.

The next test comes quickly. If the announcement lands this week and the February timetable holds, Wolfram Resources stops being a precious metals shell and becomes the public face of one of Britain's more unusual biotech bets.

via cityam.com (Source)

Share this article:

More from Priya Raman

Priya Raman

Show full bio

Senior reporter covering technology and product news in corporate strategy and chief-executive leadership at CEO Frontier.

460 articles

Filed under

Adjacent sheets

« Previous articleNext article »

End of sheetN-77 / M8 · November 16, 2026